NCT06406465View on ClinicalTrials.gov

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2028

Conditions
Carcinoma, NeuroendocrineTumor, NeuroendocrineTumors, NeuroendocrineNeuroendocrine; CarcinomaSmall Cell; Receptors
Interventions
DRUG

Belinostat

400mg/m\^2/24h or 600 mg/m\^2/24h IV over (48h continuous infusion) on days 1, 2 and 3 based on UGT1A1 status

DRUG

Cisplatin

60 mg/m\^2 IV over 60 minutes on day 2

DRUG

Etoposide

80 mg/m\^2 IV over 60 minutes on day 2 after infusion of cisplatin and again on days 3 and 4

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH